Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease

Affiliations

• ¹ Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.J.M., V.P.T., A.F.H.).
• ² Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas Health Science Center, Houston (D.A.).
• ³ AstraZeneca Research and Development, Gaithersburg, MD (J.C., S.M.G., N.I., P.Ö.).
• ⁴ Department of Medicine and Therapeutics, The Chinese Uni-versity of Hong Kong (A.P.K.).
• ⁵ Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (N.S.).
• ⁶ Don Beaven Medical Research Centre, Christchurch Hospital, New Zealand (R.S.S.).
• ⁷ Queensland Advanced Heart Failure and Cardiac Transplant Unit, The Prince Charles Hospital, and School of Clinical Medicine, The University of Queensland, Australia (Y.W.W.).
• ⁸ Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, United Kingdom (R.R.H.).